Intrinsic value of Infinity Pharmaceuticals - INFI

Previous Close

$2.04

  Intrinsic Value

$0.37

stock screener

  Rating & Target

str. sell

-82%

Previous close

$2.04

 
Intrinsic value

$0.37

 
Up/down potential

-82%

 
Rating

str. sell

We calculate the intrinsic value of INFI stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -82.57
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  19
  30
  47
  70
  102
  144
  198
  265
  348
  448
  566
  703
  860
  1,036
  1,233
  1,450
  1,686
  1,942
  2,218
  2,512
  2,824
  3,154
  3,501
  3,866
  4,248
  4,647
  5,063
  5,496
  5,946
  6,415
  6,901
Variable operating expenses, $m
 
  62
  96
  144
  209
  295
  406
  545
  715
  920
  1,163
  1,444
  1,765
  2,127
  2,531
  2,976
  3,462
  3,988
  4,553
  5,157
  5,798
  6,475
  7,189
  7,937
  8,721
  9,540
  10,393
  11,282
  12,207
  13,169
  14,169
Fixed operating expenses, $m
 
  11
  12
  12
  12
  12
  13
  13
  13
  14
  14
  14
  15
  15
  16
  16
  16
  17
  17
  18
  18
  18
  19
  19
  20
  20
  21
  21
  22
  23
  23
Total operating expenses, $m
  50
  73
  108
  156
  221
  307
  419
  558
  728
  934
  1,177
  1,458
  1,780
  2,142
  2,547
  2,992
  3,478
  4,005
  4,570
  5,175
  5,816
  6,493
  7,208
  7,956
  8,741
  9,560
  10,414
  11,303
  12,229
  13,192
  14,192
Operating income, $m
  -31
  -43
  -61
  -86
  -119
  -164
  -221
  -292
  -380
  -486
  -610
  -755
  -920
  -1,106
  -1,314
  -1,542
  -1,792
  -2,062
  -2,352
  -2,662
  -2,992
  -3,340
  -3,706
  -4,091
  -4,493
  -4,913
  -5,352
  -5,808
  -6,283
  -6,777
  -7,290
EBITDA, $m
  -28
  -38
  -54
  -75
  -103
  -141
  -190
  -251
  -325
  -415
  -521
  -644
  -784
  -943
  -1,119
  -1,314
  -1,526
  -1,755
  -2,002
  -2,266
  -2,546
  -2,842
  -3,153
  -3,480
  -3,822
  -4,180
  -4,552
  -4,941
  -5,344
  -5,764
  -6,201
Interest expense (income), $m
  1
  1
  1
  3
  4
  7
  10
  15
  20
  27
  35
  44
  55
  68
  82
  98
  115
  135
  155
  177
  201
  226
  253
  281
  310
  341
  373
  406
  441
  477
  515
Earnings before tax, $m
  -30
  -44
  -62
  -88
  -124
  -171
  -231
  -307
  -400
  -513
  -645
  -799
  -975
  -1,174
  -1,396
  -1,640
  -1,907
  -2,197
  -2,508
  -2,840
  -3,193
  -3,566
  -3,959
  -4,371
  -4,803
  -5,254
  -5,725
  -6,215
  -6,724
  -7,254
  -7,805
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -30
  -44
  -62
  -88
  -124
  -171
  -231
  -307
  -400
  -513
  -645
  -799
  -975
  -1,174
  -1,396
  -1,640
  -1,907
  -2,197
  -2,508
  -2,840
  -3,193
  -3,566
  -3,959
  -4,371
  -4,803
  -5,254
  -5,725
  -6,215
  -6,724
  -7,254
  -7,805

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  92
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  126
  54
  84
  126
  182
  257
  354
  475
  623
  802
  1,013
  1,258
  1,538
  1,854
  2,206
  2,593
  3,017
  3,475
  3,967
  4,493
  5,052
  5,642
  6,264
  6,916
  7,599
  8,313
  9,056
  9,831
  10,637
  11,475
  12,346
Adjusted assets (=assets-cash), $m
  34
  54
  84
  126
  182
  257
  354
  475
  623
  802
  1,013
  1,258
  1,538
  1,854
  2,206
  2,593
  3,017
  3,475
  3,967
  4,493
  5,052
  5,642
  6,264
  6,916
  7,599
  8,313
  9,056
  9,831
  10,637
  11,475
  12,346
Revenue / Adjusted assets
  0.559
  0.556
  0.560
  0.556
  0.560
  0.560
  0.559
  0.558
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
  0.559
Average production assets, $m
  26
  41
  63
  94
  137
  193
  265
  356
  468
  602
  760
  944
  1,154
  1,391
  1,655
  1,945
  2,263
  2,607
  2,976
  3,371
  3,790
  4,233
  4,699
  5,188
  5,701
  6,236
  6,794
  7,375
  7,980
  8,608
  9,262
Working capital, $m
  78
  -22
  -35
  -52
  -75
  -106
  -146
  -196
  -257
  -330
  -417
  -518
  -634
  -764
  -909
  -1,068
  -1,243
  -1,432
  -1,634
  -1,851
  -2,081
  -2,324
  -2,581
  -2,849
  -3,131
  -3,425
  -3,731
  -4,050
  -4,382
  -4,728
  -5,086
Total debt, $m
  20
  25
  52
  89
  140
  208
  294
  403
  537
  698
  888
  1,108
  1,360
  1,644
  1,961
  2,310
  2,691
  3,103
  3,547
  4,020
  4,523
  5,054
  5,613
  6,201
  6,815
  7,457
  8,127
  8,824
  9,549
  10,304
  11,087
Total liabilities, $m
  43
  49
  76
  113
  164
  232
  318
  427
  561
  722
  912
  1,132
  1,384
  1,668
  1,985
  2,334
  2,715
  3,127
  3,571
  4,044
  4,547
  5,078
  5,637
  6,225
  6,839
  7,481
  8,151
  8,848
  9,573
  10,328
  11,111
Total equity, $m
  82
  5
  8
  13
  18
  26
  35
  47
  62
  80
  101
  126
  154
  185
  221
  259
  302
  347
  397
  449
  505
  564
  626
  692
  760
  831
  906
  983
  1,064
  1,148
  1,235
Total liabilities and equity, $m
  125
  54
  84
  126
  182
  258
  353
  474
  623
  802
  1,013
  1,258
  1,538
  1,853
  2,206
  2,593
  3,017
  3,474
  3,968
  4,493
  5,052
  5,642
  6,263
  6,917
  7,599
  8,312
  9,057
  9,831
  10,637
  11,476
  12,346
Debt-to-equity ratio
  0.244
  4.590
  6.140
  7.090
  7.680
  8.070
  8.320
  8.490
  8.610
  8.700
  8.760
  8.810
  8.840
  8.870
  8.890
  8.910
  8.920
  8.930
  8.940
  8.950
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
Adjusted equity ratio
  -0.294
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -30
  -44
  -62
  -88
  -124
  -171
  -231
  -307
  -400
  -513
  -645
  -799
  -975
  -1,174
  -1,396
  -1,640
  -1,907
  -2,197
  -2,508
  -2,840
  -3,193
  -3,566
  -3,959
  -4,371
  -4,803
  -5,254
  -5,725
  -6,215
  -6,724
  -7,254
  -7,805
Depreciation, amort., depletion, $m
  3
  5
  7
  11
  16
  23
  31
  42
  55
  71
  89
  111
  136
  164
  195
  229
  266
  307
  350
  397
  446
  498
  553
  610
  671
  734
  799
  868
  939
  1,013
  1,090
Funds from operations, $m
  -183
  -39
  -55
  -77
  -108
  -148
  -200
  -265
  -345
  -442
  -556
  -688
  -840
  -1,011
  -1,201
  -1,412
  -1,641
  -1,890
  -2,157
  -2,443
  -2,747
  -3,068
  -3,406
  -3,761
  -4,132
  -4,521
  -4,925
  -5,347
  -5,786
  -6,242
  -6,716
Change in working capital, $m
  -29
  -8
  -12
  -17
  -23
  -31
  -40
  -50
  -61
  -74
  -87
  -101
  -115
  -130
  -145
  -160
  -174
  -189
  -203
  -217
  -230
  -243
  -256
  -269
  -281
  -294
  -306
  -319
  -332
  -345
  -359
Cash from operations, $m
  -154
  -31
  -43
  -60
  -84
  -117
  -160
  -215
  -284
  -368
  -469
  -587
  -724
  -881
  -1,056
  -1,252
  -1,467
  -1,701
  -1,955
  -2,227
  -2,517
  -2,825
  -3,150
  -3,492
  -3,851
  -4,227
  -4,619
  -5,028
  -5,454
  -5,897
  -6,357
Maintenance CAPEX, $m
  0
  -3
  -5
  -7
  -11
  -16
  -23
  -31
  -42
  -55
  -71
  -89
  -111
  -136
  -164
  -195
  -229
  -266
  -307
  -350
  -397
  -446
  -498
  -553
  -610
  -671
  -734
  -799
  -868
  -939
  -1,013
New CAPEX, $m
  -1
  -15
  -22
  -31
  -43
  -56
  -72
  -91
  -111
  -134
  -158
  -184
  -210
  -237
  -264
  -291
  -318
  -344
  -369
  -395
  -419
  -443
  -466
  -489
  -512
  -535
  -558
  -581
  -605
  -629
  -653
Cash from investing activities, $m
  40
  -18
  -27
  -38
  -54
  -72
  -95
  -122
  -153
  -189
  -229
  -273
  -321
  -373
  -428
  -486
  -547
  -610
  -676
  -745
  -816
  -889
  -964
  -1,042
  -1,122
  -1,206
  -1,292
  -1,380
  -1,473
  -1,568
  -1,666
Free cash flow, $m
  -114
  -49
  -70
  -99
  -138
  -190
  -255
  -337
  -438
  -557
  -698
  -860
  -1,045
  -1,253
  -1,484
  -1,737
  -2,013
  -2,311
  -2,631
  -2,971
  -3,332
  -3,713
  -4,114
  -4,534
  -4,974
  -5,432
  -5,911
  -6,408
  -6,926
  -7,464
  -8,023
Issuance/(repayment) of debt, $m
  0
  5
  27
  37
  51
  67
  87
  109
  134
  161
  190
  220
  252
  284
  317
  349
  381
  412
  443
  473
  503
  531
  559
  587
  615
  642
  669
  697
  725
  754
  784
Issuance/(repurchase) of shares, $m
  0
  60
  65
  93
  130
  178
  241
  319
  415
  531
  666
  824
  1,003
  1,206
  1,431
  1,679
  1,950
  2,243
  2,557
  2,892
  3,248
  3,625
  4,021
  4,436
  4,871
  5,325
  5,799
  6,292
  6,805
  7,338
  7,893
Cash from financing (excl. dividends), $m  
  0
  65
  92
  130
  181
  245
  328
  428
  549
  692
  856
  1,044
  1,255
  1,490
  1,748
  2,028
  2,331
  2,655
  3,000
  3,365
  3,751
  4,156
  4,580
  5,023
  5,486
  5,967
  6,468
  6,989
  7,530
  8,092
  8,677
Total cash flow (excl. dividends), $m
  -114
  15
  22
  31
  43
  56
  72
  91
  111
  134
  158
  184
  210
  237
  264
  291
  318
  344
  369
  394
  419
  443
  466
  489
  512
  535
  558
  581
  605
  629
  653
Retained Cash Flow (-), $m
  17
  -60
  -65
  -93
  -130
  -178
  -241
  -319
  -415
  -531
  -666
  -824
  -1,003
  -1,206
  -1,431
  -1,679
  -1,950
  -2,243
  -2,557
  -2,892
  -3,248
  -3,625
  -4,021
  -4,436
  -4,871
  -5,325
  -5,799
  -6,292
  -6,805
  -7,338
  -7,893
Prev. year cash balance distribution, $m
 
  92
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  48
  -43
  -61
  -87
  -122
  -169
  -229
  -304
  -396
  -508
  -640
  -793
  -969
  -1,167
  -1,388
  -1,632
  -1,899
  -2,187
  -2,498
  -2,830
  -3,182
  -3,555
  -3,947
  -4,359
  -4,790
  -5,241
  -5,711
  -6,200
  -6,710
  -7,239
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  46
  -39
  -53
  -72
  -95
  -122
  -154
  -190
  -228
  -266
  -304
  -339
  -368
  -392
  -408
  -415
  -413
  -403
  -385
  -360
  -329
  -295
  -259
  -222
  -186
  -153
  -123
  -96
  -73
  -55
Current shareholders' claim on cash, %
  100
  50.0
  5.2
  0.6
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.


Warning: Division by zero in /home3/webhub/public_html/x-fin.com/stocks/a-inc/ratios.php on line 11

FINANCIAL RATIOS  of  Infinity Pharmaceuticals (INFI)

Valuation Ratios
P/E Ratio -3.4
Price to Sales 5.4
Price to Book 1.3
Price to Tangible Book
Price to Cash Flow -0.7
Price to Free Cash Flow -0.7
Growth Rates
Sales Growth Rate -82.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -83.3%
Cap. Spend. - 3 Yr. Gr. Rate -12.9%
Financial Strength
Quick Ratio NaN
Current Ratio 0.3
LT Debt to Equity 24.4%
Total Debt to Equity 24.4%
Interest Coverage -29
Management Effectiveness
Return On Assets -14%
Ret/ On Assets - 3 Yr. Avg. -19.4%
Return On Total Capital -27.1%
Ret/ On T. Cap. - 3 Yr. Avg. -37.8%
Return On Equity -33.1%
Return On Equity - 3 Yr. Avg. -41.5%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -136.8%
EBITDA Margin - 3 Yr. Avg. -86.9%
Operating Margin -163.2%
Oper. Margin - 3 Yr. Avg. -94.8%
Pre-Tax Margin -157.9%
Pre-Tax Margin - 3 Yr. Avg. -95.2%
Net Profit Margin -157.9%
Net Profit Margin - 3 Yr. Avg. -95.2%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

INFI stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the INFI stock intrinsic value calculation we used $19 million for the last fiscal year's total revenue generated by Infinity Pharmaceuticals. The default revenue input number comes from 2016 income statement of Infinity Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our INFI stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for INFI is calculated based on our internal credit rating of Infinity Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Infinity Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of INFI stock the variable cost ratio is equal to 205.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $11 million in the base year in the intrinsic value calculation for INFI stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5% for Infinity Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Infinity Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the INFI stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for INFI are equal to 134.2%.

Life of production assets of 8.5 years is the average useful life of capital assets used in Infinity Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for INFI is equal to -73.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $82 million for Infinity Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 55.685 million for Infinity Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Infinity Pharmaceuticals at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
ABBV AbbVie 104.64 30.60  str.sell
CELG Celgene 102.65 35.78  str.sell
SGEN Seattle Geneti 53.48 1.07  str.sell
BMY Bristol-Myers 62.28 20.77  str.sell
JNJ Johnson&Johnso 147.36 146.14  hold
ARQL ArQule 1.73 0.10  str.sell
GILD Gilead Science 80.98 172.96  str.buy
PFE Pfizer 36.94 28.29  sell
INCY Incyte 93.16 88.49  hold

COMPANY NEWS

▶ Infinity reports 3Q loss   [Nov-07-17 08:09AM  Associated Press]
▶ Infinity to Host Investor Reception and Webcast at SITC   [Nov-06-17 08:02AM  PR Newswire]
▶ Infinity To Present At The 2017 BIO Investor Forum   [Oct-10-17 08:32AM  PR Newswire]
▶ Infinity reports 2Q loss   [Aug-03-17 11:52PM  Associated Press]
▶ Infinity to Participate in Three Upcoming Conferences   [Jun-14-17 08:32AM  PR Newswire]
▶ Infinity reports 1Q loss   [May-09-17 05:38PM  Associated Press]
▶ What Makes Valeant Pharmaceuticals (VRX) a Strong Sell?   [Mar-30-17 08:51AM  Investopedia]
▶ Should You Get Rid of Patheon (PTHN) Now?   [08:47AM  Investopedia]
▶ What Makes Tesaro (TSRO) a Strong Sell?   [08:42AM  Investopedia]
▶ Infinity Announces Organizational Changes   [08:00AM  PR Newswire]
▶ Is Infinity Pharmaceuticals Inc. (INFI) a Good Stock to Buy?   [Dec-10-16 04:38PM  at Insider Monkey]
Financial statements of INFI
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.